We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo
Medica 2024
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Quantitative Biomarker Panel Developed to Advance Cancer-Related Drug and Diagnostic Development

By LabMedica International staff writers
Posted on 11 Apr 2011
Through quantitative measurement of 101 cancer-related proteins, a quantitative biomarker panel provides researchers with unprecedented data on biologic pathways that could hold the key to understanding the molecular basis of cancer.

Rules-Based Medicine, Inc. (RBM; Austin, TX, USA), a provider of innovative biomarker solutions, reported the global launch of OncologyMAP, a powerful tool developed at the direction of and with funding from the US National Cancer Institute (NCI; Bethesda, MD, USA). OncologyMAP was released to a limited number of key customers in October 2010, and RBM has received positive feedback from clients who report valuable results in their studies for drug retasking, indication expansion, and patient stratification using this cost-effective, comprehensive testing service.

"The use of biomarker tools throughout drug development is a requirement for researchers who must balance leaner R&D budgets with the greater demands for safety, innovation, and success,” said Craig Benson, RBM president and CEO. "From one drop of serum, OncologyMAP can deliver data that could help solve therapeutic and diagnostic dilemmas related to cancer making this biomarker panel an essential component of the development toolkit.”

OncologyMAP provides drug researchers with an accurate and cost-effective means of evaluating the efficacy and safety of therapeutic candidates. The test is validated to clinical laboratory standards enabling biomarker pattern discoveries made in basic research to be reproducibly extended into clinical trials. The use of sensitive, reproducible biomarker patterns as objective measures of drug efficacy and toxicity can accelerate development efforts and facilitate decision-making to avoid costs associated with late-stage drug attrition.

OncologyMAP is based on RBM's proprietary multianalyte profiling (MAP) platform, which quantifies major blood-based biomarkers representing dozens of important biologic pathways. The multiplexing process allows for heightened efficiency while providing accuracy and precision.

Related Links:

Rules-Based Medicine


New
Gold Member
ANA & ENA Screening Assays
ANA and ENA Assays
Automated Blood Typing System
IH-500 NEXT
New
Sulfidoleukotrienes (sLT) Assay
CAST ELISA
New
Automated Cell Counter
QuadCount

Latest BioResearch News

Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns

Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma

New Method Simplifies Preparation of Tumor Genomic DNA Libraries